Studies blood and urine markers in people with IgA nephropathy
Watches blood and urine markers for kidney disease getting worse in people with IgA nephropathy.
Plain-language title generated from the registry record
Registry title: IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
Key facts
- Where
- Guangzhou, ChinaSee the site
Where in China
- The First Affiliated Hospital, Sun Yat-sen UniversityGuangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sun Yat-sen University
- Trial code
- NCT02954419
- Record updated
- 13 April 2026
- Original description
This prospective cohort study is designed to examine the association between blood and urine biomarkers (including genetic variants) and long-term kidney disease progression among 2000 Chinese IgA nephropathy patients with relatively normal kidney function (eGFR≥60 ml/min/1.73 m2).Read full original descriptionShow less
IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
This prospective cohort study is designed to examine the association between blood and urine biomarkers (including genetic variants) and long-term kidney disease progression among 2000 Chinese IgA nephropathy patients with relatively normal kidney function (eGFR≥60 ml/min/1.73 m2).
Inclusion: Male or female individuals aged 14 years or older; Patients with biopsy-proven primary IgA nephropathy; A renal biopsy available for reviewing must include 10 or more glomeruli; The first renal biopsy was performed within 3 years; eGFR ≥ 60 ml/min/1.73 m2 (MDRD formula); Individuals or their legal representative who are able to understand and have voluntarily signed the informed consent form (ICF).
Exclusion: Individuals had secondary IgA nephropathy due to diseases such as diabetes, chronic liver disease and systemic lupus erythematosus; Relatives were diagnosed with biopsy-proven primary IgA nephropathy.